Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Polyzois Makras

Showing results (81-90 of 123) with videos related to

Pageof 13
Sort By:
Hormones (Athens, Greece)|February 21, 2013
Papillary thyroid microcarcinoma presenting as lymph node metastasis--a diagnostic challenge: case report and systematic review of literatureAthanasios D Anastasilakis, Stergios A Polyzos, Polyzois Makras, et al.
JBMR Plus|April 20, 2026
Romosozumab for the treatment of thalassemia-associated osteoporosis in two female patientsMaria P Yavropoulou, Maria-Evangelia Koloutsou, Polyxeni Delaporta, et al.
American Journal of Hematology|April 19, 2023
Efficacy of denosumab monotherapy among adults with Langerhans cell histiocytosis: A prospective clinical trialPolyzois Makras, Maria P Yavropoulou, Sofia N Chatziioannou, et al.
The Journal of Clinical Endocrinology and Metabolism|January 27, 2012
Serum osteoprotegerin, RANKL, and Dkk-1 levels in adults with Langerhans cell histiocytosisPolyzois Makras, Stergios A Polyzos, Athanasios D Anastasilakis, et al.
Frontiers in Endocrinology|March 16, 2026
Modeling rebound bone loss following denosumab discontinuation and sequential zoledronate therapy in TgRANKL osteoporotic miceVagelis Rinotas, Eleftheria-Dimitra Ntouskou, Melina Dragolia, et al.
Pediatric Hematology and Oncology|February 10, 2022
Prevalence of the <i>BRAF</i> <sup>V600E</sup> mutation in Greek adults with Langerhans cell histiocytosisDimitra Stathi, Maria P Yavropoulou, Carl E Allen, et al.
Expert Opinion on Therapeutic Targets|November 15, 2014
Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatmentAthanasios D Anastasilakis, Stergios A Polyzos, Polyzois Makras, et al.
Metabolism: Clinical and Experimental|July 23, 2015
Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markersAthanasios D Anastasilakis, Stergios A Polyzos, Zoe A Efstathiadou, et al.
Archives of Osteoporosis|October 17, 2018
Serum 25-hydroxyvitamin D status, quantitative ultrasound parameters, and their determinants in Greek populationEffimia V Grigoriou, George Trovas, Nikolaos Papaioannou, et al.
Bone|July 13, 2019
Bone disease following solid organ transplantation: A narrative review and recommendations for management from The European Calcified Tissue SocietyAthanasios D Anastasilakis, Elena Tsourdi, Polyzois Makras, et al.
Pageof 13

Showing results (81-90 of 123) with videos related to

Sort By:
Pageof 13
Hormones (Athens, Greece)|February 21, 2013
Papillary thyroid microcarcinoma presenting as lymph node metastasis--a diagnostic challenge: case report and systematic review of literatureAthanasios D Anastasilakis, Stergios A Polyzos, Polyzois Makras, et al.
JBMR Plus|April 20, 2026
Romosozumab for the treatment of thalassemia-associated osteoporosis in two female patientsMaria P Yavropoulou, Maria-Evangelia Koloutsou, Polyxeni Delaporta, et al.
American Journal of Hematology|April 19, 2023
Efficacy of denosumab monotherapy among adults with Langerhans cell histiocytosis: A prospective clinical trialPolyzois Makras, Maria P Yavropoulou, Sofia N Chatziioannou, et al.
The Journal of Clinical Endocrinology and Metabolism|January 27, 2012
Serum osteoprotegerin, RANKL, and Dkk-1 levels in adults with Langerhans cell histiocytosisPolyzois Makras, Stergios A Polyzos, Athanasios D Anastasilakis, et al.
Frontiers in Endocrinology|March 16, 2026
Modeling rebound bone loss following denosumab discontinuation and sequential zoledronate therapy in TgRANKL osteoporotic miceVagelis Rinotas, Eleftheria-Dimitra Ntouskou, Melina Dragolia, et al.
Pediatric Hematology and Oncology|February 10, 2022
Prevalence of the <i>BRAF</i> <sup>V600E</sup> mutation in Greek adults with Langerhans cell histiocytosisDimitra Stathi, Maria P Yavropoulou, Carl E Allen, et al.
Expert Opinion on Therapeutic Targets|November 15, 2014
Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatmentAthanasios D Anastasilakis, Stergios A Polyzos, Polyzois Makras, et al.
Metabolism: Clinical and Experimental|July 23, 2015
Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markersAthanasios D Anastasilakis, Stergios A Polyzos, Zoe A Efstathiadou, et al.
Archives of Osteoporosis|October 17, 2018
Serum 25-hydroxyvitamin D status, quantitative ultrasound parameters, and their determinants in Greek populationEffimia V Grigoriou, George Trovas, Nikolaos Papaioannou, et al.
Bone|July 13, 2019
Bone disease following solid organ transplantation: A narrative review and recommendations for management from The European Calcified Tissue SocietyAthanasios D Anastasilakis, Elena Tsourdi, Polyzois Makras, et al.
Pageof 13